Want to see PASG full AI Analyst Report?
PASG Stock Chart & Stats
$4.94
-$0.32(-6.48%)
At close: 4:00 PM EDT
$4.94
-$0.32(-6.48%)
Day’s Range― - ―
52-Week Range$3.29 - $20.00
Previous Close$4.52
Volume29.52K
Average Volume (3M)41.18K
Market Cap
$14.51M
Enterprise Value-$8.50
Total Cash (Recent Filing)$24.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.33
Shares Outstanding3,217,810
10 Day Avg. Volume55,130
30 Day Avg. Volume41,182
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.19
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-8.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Merger Provides Capital And Governance ChangeThe all-stock merger shifts strategic control to Remix, which secured an oversubscribed $100M financing intended to fund operations into 2028. This materially improves combined access to development capital and clinical-readout funding, reducing near-term financing pressure and enabling multi-year program execution.
Improving Cash Burn TrendOperating cash outflows have narrowed substantially over several years, indicating durable cost control and lower recurring cash requirements. While still negative, the sustained improvement lengthens runway between financings and reflects structural reductions in spending intensity rather than a one-off quarter improvement.
Reduced Long-term Facility ObligationsTerminating the large office lease and previously subleasing most space reduces long-term fixed costs and facility commitments. This structural simplification lowers ongoing OPEX and enhances operational flexibility, making the company leaner and less burdened by legacy real-estate liabilities over the medium term.
Bears Say
Pre-revenue Business ModelPassage remains pre-revenue, relying entirely on collaborations, licensing, or financing to fund operations. The absence of product sales creates persistent funding dependency and execution risk: successful clinical development and regulatory approval are required before sustainable revenues emerge.
Severely Eroded Equity CushionThe dramatic decline in shareholders' equity signals heightened balance-sheet fragility and limited capacity to absorb setbacks. A very thin equity base constrains borrowing options, increases likelihood of dilutive financings, and raises solvency risk if clinical or regulatory setbacks occur.
Winding Down Core Gene-therapy OperationsThe decision to wind down gene-therapy activities, return rights, and end key manufacturing and collaboration ties materially reduces Passage's internal development capacity and future upside from its CNS portfolio. This structural rollback curtails the company’s ability to generate long-term product value on its own.
Passage Bio News
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $3.29 and its highest was $20.00 in the past 12 months.
What is Passage Bio’s market cap?
Passage Bio’s market cap is $14.51M.
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is Nov 16, 2026 which is in 82 days.
How were Passage Bio’s earnings last quarter?
Passage Bio released its earnings results on Jul 30, 2026. The company reported -$2.437 earnings per share for the quarter, beating the consensus estimate of -$2.44 by $0.003.
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Overvalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Passage Bio have?
Passage Bio has 3,217,810 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Passage Bio reported an EPS of -$2.437 in its last earnings report, beating expectations of -$2.44. Following the earnings report the stock price went down -0.664%.
Which hedge fund is a major shareholder of Passage Bio?
Currently, no hedge funds are holding shares in PASG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Passage Bio
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
PASG Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Tempest Therapeutics
―
Chemomab Therapeutics
―
Annovis Bio
―
―
Cognition Therapeutics
―
Ownership Overview
21.90% Insiders
5.49% Mutual Funds
29.70% Other Institutional Investors
39.37% Public Companies and
Individual Investors